Sorena Kiani, MBPhD, FRCP, FRCPath - Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Targeted Prophylactic Therapy?

What this episode covers

Visit https://www.peervoice.com/PBJ860 to view the entire programme with slides. After completing “Sorena Kiani, MBPhD, FRCP, FRCPath - Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Targeted Prophylactic Therapy?”, participants will be able to: Outline the latest treatment guidelines for prophylactic treatment of hereditary angioedema (HAE) and the rationale for why attenuated androgens are recommended second-line; Identify current therapies for first-line long-term prophylaxis of HAE; and Propose how to optimally manage the transition of patients with HAE from attenuated androgens to alternative prophylactic agents.

Distinct summary based on available episode metadata or transcript content.